this protocol describes a strategy for the generation of 3D prostate organoid cultures from healthy mouse and human prostate cells (either bulk or Facs-sorted single luminal and basal cells), metastatic prostate cancer lesions and circulating tumor cells. organoids derived from healthy material contain the differentiated luminal and basal cell types, whereas organoids derived from prostate cancer tissue mimic the histology of the tumor. We explain how to establish these cultures in the fully defined serum-free conditioned medium that is required to sustain organoid growth. starting with the plating of digested tissue material, full-grown organoids can usually be obtained in ~2 weeks. the culture protocol we describe here is currently the only one that allows the growth of both the luminal and basal prostatic epithelial lineages, as well as the growth of advanced prostate cancers. organoids established using this protocol can be used to study many different aspects of prostate biology, including homeostasis, tumorigenesis and drug discovery. Moreover, with our culture protocol, we have not yet succeeded in growing organoids derived from primary prostate cancers. This is probably because tumor cells do not have a selective advantage over normal cells in our prostate culture medium. On the contrary, the normal prostate cells that are present within each sample seem to overgrow the tumor cells.
IntroDuctIon
The prostate is a gland of the male reproductive system that produces seminal fluid. The pseudostratified epithelium present in the prostate consists of luminal, basal and rare neuroendocrine cells. Androgen receptor (AR) signaling is essential for prostate development and homeostasis, as well as for prostate cancer initiation and progression. As generally acknowledged 1,2 , prostate cancer research has been hampered by the lack of suitable in vitro model systems. Although powerful in vivo models are available, these are often expensive, time-consuming and technically challenging. Most in vitro research is performed using cell lines derived from neoplastic lesions, and most of these do not have an intact AR signaling pathway, making them poor representatives of healthy prostate and prostate cancer tissue. We have developed a testosterone-responsive prostate organoid culture system derived from primary prostate tissue and advanced prostate cancer tissue 3, 4 , which opens new opportunities to study prostate homeostasis and cancer. In this protocol, we provide further details of how to set up and evaluate these culture systems.
Comparison with other methods
The culture system we describe here was developed by adapting and optimizing the culture conditions that were previously used to establish mouse and human small intestine and colon organoid cultures 5, 6 . We added different compounds and growth factors to generic organoid medium (containing epidermal growth factor (EGF), Noggin and R-spondin 1 (Box 1) 5 ), enabling us to establish culture conditions that support the long-term growth of mouse and human prostate tissue and advanced prostate cancers. The composition of the medium we use is summarized in Table 1 . By using this culture system, we have shown that: (i) both the luminal and basal lineages harbor multipotent progenitor cells and can be propagated for long-term growth, (ii) organoids functionally recapitulate AR signaling, (iii) organoids derived from prostate cancer mouse models recapitulate mouse phenotypes and (iv) human prostate cancer-derived organoids genetically and phenotypically mimic the tumor from which they were derived 3, 4 .
Several groups have demonstrated the in vitro growth of primary prostatic tissue. However, in contrast to our prostate organoid cultures, most of these models only support shortterm growth, mainly support growth of basal cells and do not allow for full luminal differentiation (limiting androgen responsiveness) [7] [8] [9] [10] . Moreover, these methods do not allow efficient growth of prostate cancer tissue. A protocol developed by Liu et al. 11 enables the indefinite growth of reprogrammed prostatic epithelial cells. Interestingly, the Rho-associated kinase (ROCK) inhibitor Y-27632 and the presence of feeder cells-producing factors that may also be present in our defined prostate culture medium-are essential in this system. However, cells cultured under these conditions do not closely resemble the in vivo prostate, and, additionally, androgen responsiveness is limited in this system. Finally, Chua et al. 12 recently demonstrated a culture system that exclusively allows the growth of organoids from single luminal cells, albeit at a lower plating efficiency than reported with our method (0.2-0.3% described by Chua et al. 12 versus 1-2% when using our method 3 ). Under these conditions, organoids that resemble the in vivo prostate are formed. However, basal cell-derived organoids cannot be propagated for a prolonged time. In addition, in contrast to our method, their medium is not fully defined. It is possible that the medium's undefined additions (e.g., fetal calf serum) contain growth factors that are present in our defined medium. No studies to date have investigated whether prostate cancer tissue can be propagated under these conditions.
Limitations of the method
With an average split ratio of 1:2 every 2 weeks, the proliferation rate of sorted human luminal cells is not very high. Organoid lines derived from advanced prostate cancers may have a similarly Organoid culture systems for prostate epithelial and cancer tissue low average proliferation rate, although this rate can vary greatly between cultures derived from different donors.
Moreover, with our culture protocol, we have not yet succeeded in growing organoids derived from primary prostate cancers. This is probably because tumor cells do not have a selective advantage over normal cells in our prostate culture medium. On the contrary, the normal prostate cells that are present within each sample seem to overgrow the tumor cells.
Experimental design
Overview of the procedure. The following step-by-step procedure describes how to obtain mouse and human prostate organoids from healthy prostate tissue and advanced prostate cancers. The main procedure (Steps 1-3) describes the dissection and digestion of tissue, as well as the subsequent cell plating and organoid passaging. Organoids are plated in Matrigel and cultured in defined prostate culture medium, which is refreshed every 2-3 d. Box 2 describes how to culture organoids derived specifically from luminal and basal lineages. Separation of luminal and basal lineages requires antibody staining and FACS separation. We also describe protocols for cryopreservation of the organoids once they have been established (Step 4A), RNA isolation and cDNA production (Step 4B), and genomic DNA isolation (Step 4C). The organoids are genetically and phenotypically stable, and they can be genetically modified using many different genome editing systems 3, 4, [13] [14] [15] [16] , making them a very suitable tool for studying tissue homeostasis and cancer.
Culture medium. In this protocol, mouse and human prostate organoids are grown in defined prostate culture medium containing R-spondin 1. Either R-spondin 1-conditioned medium (for preparation, see Box 1) or recombinant R-spondin 1 (R&D Systems) at a final concentration of 500 ng/ml can be used. We have not observed any differences in organoid establishment, maintenance or morphology when using prostate culture medium containing either R-spondin 1-conditioned medium or recombinant R-spondin 1. To achieve high efficiency for culture establishment and successful maintenance, it is essential to use fresh medium (stored at 4 °C for not more than 1 week) and to use effective and appropriately stored growth factors and chemical compounds.
Mouse age. To establish mouse prostate organoids, prostates should be isolated from mice that are at least 8 weeks old. The maximum age of the mice for efficient organoid establishment has not been carefully addressed. However, we have successfully established organoids from mice with an age of up to 2 years.
Controls.
The separation of luminal and basal cells from mouse and human prostate tissue (Box 2) is based on double antibody staining for marker gene expression followed by FACS. To specifically stain luminal cells, we use conjugated antibodies against CD26 and CD24 (human and mouse, respectively). For specific staining of basal cells, we use a conjugated CD49f-specific antibody for both human and mouse. As a negative control, an isotype-matched control antibody generated from the same species as the target antibody can be used. In addition, single-color staining controls (staining for either the luminal or basal marker) can also be included.
To verify that the organoids are indeed derived from prostate tissue, (q-) RT-PCR can be performed for the expression of prostatespecific genes (see ANTICIPATED RESULTS and Karthaus et al. 3 ). In addition, to confirm the growth of prostate tumor organoids, whole-genome sequencing can be performed to analyze mutation spectra 4 . In this protocol, we also describe the procedures to isolate RNA, produce cDNA and isolate genomic DNA from organoids. ? troublesHootInG 17. Isolate the cells using FACS (Fig. 3) . On average, 200 mg of prostate tissue should contain ~150,000 luminal cells and 600,000 basal cells. ? troublesHootInG 18. Plate luminal and basal cells as described in Step 2A(xiv-xvii) (for mouse cells) and Step 2B(viii-x) (for human cells) of the main PROCEDURE (Fig. 3) . 19 . Refresh the medium with Y-27632 dihydrochloride every 2-3 d and check organoid growth using a light microscope. After 2-3 d, organoids should appear from basal cells, whereas small organoids should appear from luminal cells after 5-7 d. For culture beyond 7 d, do not include Y-27632 dihydrochloride in the medium. From 7 d onward, medium without Y-27632 dihydrochloride should be used. 20. After ~14 d, passage organoids as described in PROCEDURE Step 3A (mouse) and Step 3B (human).
REAGENT SETUP Mouse and human material The procedure can be applied to whole mouse prostate, pieces of human prostate tissue (minimum size 1 mm 3 ), pieces of human metastasis biopsy (minimum size 1 mm 3 ) or blood samples from patients with advanced prostate cancer (8 ml of blood is required). We have successfully grown organoids from all these starting materials 3, 4 . Although fresh material should preferably be used, we have been able to establish organoids from both mouse and human tissue stored overnight at 4 °C in adDMEM/F12 +/+/+ (i.e., adDMEM/F12 containing penicillin/streptomycin, 10 mM HEPES and 2 mM GlutaMAX (100× diluted)). ! cautIon All mouse experiments must be in compliance with local animal welfare laws and guidelines. ! cautIon Informed consent must be obtained from all subjects. Studies must conform to all relevant institutional and governmental regulations. Mouse prostate culture medium The final medium composition is summarized in Table 1 . To make up the medium, combine 1.0 ml of B27, 125.0 µl of N-acetyl-l-cysteine (500 mM in PBS), 5.0 µl of EGF (0.5 mg/ml in PBS + 0.1% (wt/vol) BSA), 2.0 µl of A83-01 (5 mM in DMSO), 50.0 µl of Noggin (100 µg/ml in PBS + 0.1% (wt/vol) BSA), 50.0 µl of R-spondin 1 (500 µg/ml in PBS + 0.1% (wt/vol) BSA or 10% conditioned medium) and 50.0 µl of dihydrotestosterone (1 µM in ethanol). Top it up to 50 ml with adDMEM/F12 +/+/+).  crItIcal As detailed in the PROCEDURE, after cell passaging, Y-27632 dihydrochloride (ROCK inhibitor) should be included in the culture medium to a final concentration of 10 µM. To make up this medium, add 5.0 µl of 100 mM Y-27632 dihydrochloride to 50 ml of mouse prostate culture medium.  crItIcal The culture medium should not be stored for longer than 1 week at 4 °C. Human prostate culture medium The final medium composition is summarized in Table 1 (i) Euthanize a male mouse at <8 weeks of age, and then isolate the urogenital system (Fig. 1a) .
(ii) Remove the seminal vesicles by breaking or cutting the blood vessels and connective tissue and making an incision at the base of the urethra (Fig. 1b,c ; for a detailed isolation protocol of the mouse prostate, see ref. 17 ). (iii) Remove the vas deferens by cutting it near the prostate (Fig. 1d) . (iv) Remove the bladder by cutting it near the base of the urethra (Fig. 1e) . (v) Remove the remaining vesicles and fat tissue by gently cutting (Fig. 1f) . (vi) Remove the urethra; carefully pull the prostate lobes so that they are no longer attached to the urethra (Fig. 1g) .
 crItIcal step Do not isolate the ampullary gland, which is located between the two lobes of the anterior prostate (Fig. 1i,j) but is not considered to be part of the prostate. (vii) Isolate each lobe individually (anterior prostate, ventral prostate and dorsolateral prostate); alternatively, continue with the whole prostate (Fig. 1g,h,k (Fig. 2a and table 2 ). On average, one whole prostate will yield 25 drops.  crItIcal step Work quickly to ensure that the Matrigel does not solidify before plating.  crItIcal step To ensure efficient plating, do not dilute the Matrigel too much. The average final percentage of Matrigel should be ~75%. (xv) Place the tissue culture plate upside down in the CO 2 incubator (5% CO 2 , 37 °C) for 15 min to allow the Matrigel to solidify.  crItIcal step The plate should be placed upside down in the incubator to prevent adherence to the plate bottom. (xvi) Prewarm the mouse prostate culture medium in a 37 °C water bath for ~10 min before adding it to the organoids. (xvii) Gently pipette 500 µl of prewarmed (37 °C) mouse prostate culture medium plus 10 µM Y-27632 dihydrochloride into each well, and then place the plate into the CO 2 incubator (5% CO 2 , 37 °C). (viii) Count the cells using a hemocytometer, and plate ~20,000 cells in a 40-µl drop in the middle of one well of a 24-well plate ( Fig. 2a and table 2) .  crItIcal step Work quickly to ensure that the Matrigel does not solidify before plating.  crItIcal step To ensure efficient plating, do not dilute the Matrigel too much. The average final percentage of Matrigel should be ~75%. (ix) Place the plate into the CO 2 incubator (5% CO 2 , 37 °C) for 15 min to allow the Matrigel to solidify.  crItIcal step Place the plate upside down in the incubator to prevent adherence to the plate bottom. (x) Gently pipette 500 µl of prewarmed (~10 min in a 37 °C water bath) human prostate culture medium plus 10 µM Y-27632 dihydrochloride into each well, and place the plate into a CO 2 incubator (5% CO 2 , 37 °C). (xi) Replace the medium with medium containing 10 µM Y-27632 dihydrochloride every 2-3 d and continue to culture for 7 d. (xii) At the next culture change after the initial 7 d of culture, replace the medium with medium that does not contain Y-27632 dihydrochloride. Proceed to the next step (organoid passage) 1-2 weeks after starting the culture.  crItIcal step Human organoids should be split at a 1:2 ratio every 1-2 weeks. The exact timing is dependent on the density and whether the organoids are derived from luminal or basal lineages. For instance, the day 7 basal-derived and the day 14 luminal-derived organoids depicted in Fig. 3b are of the size and density to be passaged. 2C(vi,vii) ). • tIMInG Steps 1-3, establishing and culturing prostate organoid cultures: variable; up to ~2 weeks Step 4, downstream assays: variable box 1, preparation of R-spondin 1-conditioned medium: 10-11 d box 2, establishment of luminal cell-and basal cell-derived organoid cultures: 14 d
antIcIpateD results
This protocol describes an efficient method for establishing organoid cultures from mouse and human prostate tissue. The efficiency of establishing these cultures is >95%, although the efficiency of organoid establishment from advanced prostate cancers is substantially lower (~15-20%), mainly because of the small amount of input material. After sorting, basal cells have an organoid-forming capacity of ~70% (of which >95% are solid), whereas ~1-2% of sorted luminal cells give rise to organoids (>95% are cystic). To reach these efficiencies and to maintain growth, it is essential to use fresh medium (stored at 4 °C for no longer than 1 week) and to use effective and appropriately stored growth factors and chemical compounds. Prostate organoids can be genetically modified 3 , and they can thus be used to study the involvement of genes in prostate homeostasis and cancer. We have not been successful in growing organoids derived from primary prostate cancers, most probably because of overgrowth by normal prostate epithelium present within each sample.
For mouse and human organoid culture, small organoids can usually be detected within 2-3 d after plating (Figs. 2b  and 3a,b) . Mouse organoids are generally cystic (Figs. 2b and 3a) , whereas unsorted newly established human organoid cultures mainly consist of solid basal cell-derived organoids during the initial passages. After 5-7 d, small cystic organoids can be observed from sorted luminal cells (Fig. 3b) . The morphology of organoids derived from advanced prostate cancers can vary greatly between patients (e.g., cystic and solid structures) and-because of tumor heterogeneity-even within cultures derived from the same patient 4 .
To confirm that the organoids are indeed derived from prostate tissue, expression of prostate-specific genes such as that encoding prostate-specific antigen (PSA) can be determined. Expression analysis of luminal-specific markers (e.g., the AR cytokeratin 8, cytokeratin 18, probasin, PSA) and basal-specific markers (e.g., p63, cytokeratin 5) should be used to confirm the presence of both lineages in the established cultures 3 .
For samples derived from advanced prostate cancers, growth speed and morphology are highly variable (ranging from weekly 1:2-1:3 split ratios to monthly 1:2-1:3 split ratios). Confirmation of the cancerous origin of these organoids can be achieved by genomic analysis either by whole-genome sequencing or by comparative genomic hybridization 4 . 
